| 'No risk, no fun': challenges for the oncology phase I clinical trial time-performance. | |
| | |
MedLine Citation:
|
PMID: 18951015 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Drug development in oncology is faced with the challenge of making active new compounds available for standard of care in the shortest possible time frame. While rules and regulations create an accepted factor in delaying trial execution, protocol issues and procedures are more often a delay factor than needed, particularly in industry-sponsored studies. This provides an option to decrease trial time, without affecting patient safety. Among the possible rooms for improvement are a balanced use of in- and exclusion criteria, justified by animal toxicology, and flexible dose escalation steps still defined a priori. It is also of crucial importance to make sure in the phase I programme that the pharmacology of the agent involved is appropriately understood. Including real-time pharmacokinetics, food-effect studies and, if possible, bioavailability studies in the phase I programme would decrease the risk of taking the wrong decisions for follow-on development. The concept of increasing the number of study sites to speed up accrual has a negative effect on trial execution and is actually a delay factor that in addition has the intrinsic risk of putting patient safety at stake. |
| | |
Authors:
|
Jaap Verweij |
Related Documents
:
|
16006485 - Establishing scales of perceived severity for clinical situations during anaesthesia. 23270995 - Concordance of self- and proxy-rated worry and anxiety symptoms in older adults with de... 23679795 - Factors that influence obesity, functional capacity, anxiety and depression outcomes fo... 7603935 - The effect of adjunct questions on older adults' recall of information from a patient e... 23672375 - Social problem-solving, perceived stress, depression and life-satisfaction in patients ... 6885285 - On the validity of the symptom check list-90 (scl90): a comparison of diagnostic self-r... |
Publication Detail:
|
Type: Journal Article Date: 2008-10-22 |
Journal Detail:
|
Title: European journal of cancer (Oxford, England : 1990) Volume: 44 ISSN: 1879-0852 ISO Abbreviation: Eur. J. Cancer Publication Date: 2008 Nov |
Date Detail:
|
Created Date: 2008-11-10 Completed Date: 2009-03-16 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9005373 Medline TA: Eur J Cancer Country: England |
Other Details:
|
Languages: eng Pagination: 2600-7 Citation Subset: IM |
Affiliation:
|
Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands. j.verweij@erasmusmc.nl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
adverse effects,
pharmacokinetics,
therapeutic use* Biological Availability Clinical Protocols Clinical Trials, Phase I as Topic / methods* Dose-Response Relationship, Drug Food-Drug Interactions Humans Maximum Tolerated Dose Neoplasms / drug therapy* Tumor Markers, Biological |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Tumor Markers, Biological |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Modification of carbon nanotubes with redox hydrogel: improvement of amperometric sensing sensitivit...
Next Document: Development of a mutant of Trichoderma citrinoviride for enhanced production of cellulases.